Mr. Terry Booth reports

AURORA CANNABIS PROVIDES UPDATE ON GERMAN CANNABIS PRODUCTION TENDER

Aurora Cannabis Inc. has confirmed that, further to its press release dated April 5, 2019, the public appeal process related to the German cannabis production tender has been completed, and Aurora's contract with the German Federal Institute for Drugs and Medical Devices (Bundesinstitut fur Arzneimittel und Medizinprodukte BfArM) has now been finalized.

The approval will allow Aurora to begin construction of a new, state-of-the art, indoor cannabis production facility in Leuna, Germany, in May, 2019, and the company anticipates completion within 12 months of groundbreaking. Initial shipments of locally grown cannabis are expected to become available to German medical patients starting in October, 2020, with the new facility producing a minimum of 4,000 kilograms over a four-year period, to be expanded over time as regulations permit.

"We are thrilled with the positive outcome of the tender process, and excited to start construction on our latest production facility," said Neil Belot, chief global business development officer. "We are very proud of the work done by our European team. In addition to providing German medical patients with a local supply of high-quality, medical-grade cannabis, this new facility will also bring additional new jobs to the German labour market. It's a strong validation of our production and distribution standards to have been recognized as having the highest-rated overall concept out of 79 tender applications, and we look forward to continuing to increase availability of medical cannabis in this important market."

"Our successful proposal was focused on implementing the Aurora standard, pharmaceutical-grade, cultivation techniques, while leveraging the broad competences of our team of architects, engineers, pharmacists, plant specialists and project management professionals," said Dr. Axel Gille, managing director of Aurora Europe. "Construction of this new facility in Leuna is the next logical step in expanding our Europe-wide production network to ensure medical patients have safe access to consistent, high-quality medicinal cannabis flowers and full extracts."

About Aurora Cannabis Inc.

Headquartered in Edmonton, Alta., Canada, with financed capacity in excess of 625,000 kg per annum and sales and operations in 24 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

We seek Safe Harbor.